دورية أكاديمية
أعرض في EDS

Factors Associated With Severe COVID-19 Among Vaccinated Adults Treated in US Veterans Affairs Hospitals.

التفاصيل البيبلوغرافية
العنوان: Factors Associated With Severe COVID-19 Among Vaccinated Adults Treated in US Veterans Affairs Hospitals.
المؤلفون: Vo AD; VA Boston Cooperative Studies Program, Boston, Massachusetts., La J; VA Boston Cooperative Studies Program, Boston, Massachusetts., Wu JT; VA Palo Alto Healthcare System, Palo Alto, California.; Stanford University School of Medicine, Stanford, California., Strymish JM; Department of Medicine, VA Boston Healthcare System, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Ronan M; Department of Medicine, VA Boston Healthcare System, Boston, Massachusetts., Brophy M; VA Boston Cooperative Studies Program, Boston, Massachusetts.; Department of Medicine, VA Boston Healthcare System, Boston, Massachusetts.; Boston University School of Medicine, Boston, Massachusetts., Do NV; VA Boston Cooperative Studies Program, Boston, Massachusetts.; Department of Medicine, VA Boston Healthcare System, Boston, Massachusetts.; Boston University School of Medicine, Boston, Massachusetts., Branch-Elliman W; VA Boston Cooperative Studies Program, Boston, Massachusetts.; Department of Medicine, VA Boston Healthcare System, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; VA Boston Center for Healthcare Organization and Implementation Research, Boston, Massachusetts., Fillmore NR; VA Boston Cooperative Studies Program, Boston, Massachusetts.; Department of Medicine, VA Boston Healthcare System, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Dana Farber Cancer Institute, Boston, Massachusetts., Monach PA; VA Boston Cooperative Studies Program, Boston, Massachusetts.; Department of Medicine, VA Boston Healthcare System, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.
المصدر: JAMA network open [JAMA Netw Open] 2022 Oct 03; Vol. 5 (10), pp. e2240037. Date of Electronic Publication: 2022 Oct 03.
نوع المنشور: Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
اللغة: English
بيانات الدورية: Publisher: American Medical Association Country of Publication: United States NLM ID: 101729235 Publication Model: Electronic Cited Medium: Internet ISSN: 2574-3805 (Electronic) Linking ISSN: 25743805 NLM ISO Abbreviation: JAMA Netw Open Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Chicago, IL : American Medical Association, [2018]-
مواضيع طبية MeSH: COVID-19*/epidemiology , COVID-19*/prevention & control , Veterans*, Humans ; Adult ; United States/epidemiology ; Male ; Middle Aged ; Aged, 80 and over ; Female ; Retrospective Studies ; COVID-19 Vaccines/therapeutic use ; SARS-CoV-2 ; Hospitals, Veterans ; Antiviral Agents ; Dexamethasone ; Oxygen
مستخلص: Importance: With a large proportion of the US adult population vaccinated against SARS-CoV-2, it is important to identify who remains at risk of severe infection despite vaccination.
Objective: To characterize risk factors for severe COVID-19 disease in a vaccinated population.
Design, Setting, and Participants: This nationwide, retrospective cohort study included US veterans who received a SARS-CoV-2 vaccination series and later developed laboratory-confirmed SARS-CoV-2 infection and were treated at US Department of Veterans Affairs (VA) hospitals. Data were collected from December 15, 2020, through February 28, 2022.
Exposures: Demographic characteristics, comorbidities, immunocompromised status, and vaccination-related variables.
Main Outcomes and Measures: Development of severe vs nonsevere SARS-CoV-2 infection. Severe disease was defined as hospitalization within 14 days of a positive SARS-CoV-2 diagnostic test and either blood oxygen level of less than 94%, receipt of supplemental oxygen or dexamethasone, mechanical ventilation, or death within 28 days. Association between severe disease and exposures was estimated using logistic regression models.
Results: Among 110 760 patients with infections following vaccination (97 614 [88.1%] men, mean [SD] age at vaccination, 60.8 [15.3] years; 26 953 [24.3%] Black, 11 259 [10.2%] Hispanic, and 71 665 [64.7%] White), 10 612 (9.6%) had severe COVID-19. The strongest association with risk of severe disease after vaccination was age, which increased among patients aged 50 years or older with an adjusted odds ratio (aOR) of 1.42 (CI, 1.40-1.44) per 5-year increase in age, such that patients aged 80 years or older had an aOR of 16.58 (CI, 13.49-20.37) relative to patients aged 45 to 50 years. Immunocompromising conditions, including receipt of different classes of immunosuppressive medications (eg, leukocyte inhibitor: aOR, 2.80; 95% CI, 2.39-3.28) or cytotoxic chemotherapy (aOR, 2.71; CI, 2.27-3.24) prior to breakthrough infection, or leukemias or lymphomas (aOR, 1.87; CI, 1.61-2.17) and chronic conditions associated with end-organ disease, such as heart failure (aOR, 1.74; CI, 1.61-1.88), dementia (aOR, 2.01; CI, 1.83-2.20), and chronic kidney disease (aOR, 1.59; CI, 1.49-1.69), were also associated with increased risk. Receipt of an additional (ie, booster) dose of vaccine was associated with reduced odds of severe disease (aOR, 0.50; CI, 0.44-0.57).
Conclusions and Relevance: In this nationwide, retrospective cohort of predominantly male US Veterans, we identified risk factors associated with severe disease despite vaccination. Findings could be used to inform outreach efforts for booster vaccinations and to inform clinical decision-making about patients most likely to benefit from preexposure prophylaxis and antiviral therapy.
التعليقات: Erratum in: JAMA Netw Open. 2023 Feb 1;6(2):e231692. (PMID: 36780167)
References: N Engl J Med. 2021 Dec 9;385(24):e85. (PMID: 34706170)
MMWR Morb Mortal Wkly Rep. 2022 Jan 07;71(1):19-25. (PMID: 34990440)
Lancet. 2022 Mar 5;399(10328):924-944. (PMID: 35202601)
MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):458-464. (PMID: 32298251)
N Engl J Med. 2022 Sep 1;387(9):790-798. (PMID: 36001529)
Aliment Pharmacol Ther. 2022 May;55(10):1244-1264. (PMID: 35355306)
JAMA Intern Med. 2022 Feb 1;182(2):153-162. (PMID: 34962505)
Infect Control Hosp Epidemiol. 2022 Jan 11;:1-24. (PMID: 35012694)
Clin Microbiol Infect. 2022 Feb;28(2):163-177. (PMID: 35020589)
Infect Control Hosp Epidemiol. 2022 May 23;:1-3. (PMID: 35599374)
N Engl J Med. 2021 Oct 7;385(15):1393-1400. (PMID: 34525275)
N Engl J Med. 2021 Oct 7;385(15):1431-1433. (PMID: 34496195)
Int J Infect Dis. 2020 May;94:91-95. (PMID: 32173574)
Nat Med. 2022 Apr;28(4):831-837. (PMID: 35045566)
N Engl J Med. 2022 Jan 27;386(4):340-350. (PMID: 35021002)
Blood. 2019 Jun 13;133(24):2615-2618. (PMID: 31003998)
MMWR Morb Mortal Wkly Rep. 2020 Apr 03;69(13):382-386. (PMID: 32240123)
المشرفين على المادة: 0 (COVID-19 Vaccines)
0 (Antiviral Agents)
7S5I7G3JQL (Dexamethasone)
S88TT14065 (Oxygen)
تواريخ الأحداث: Date Created: 20221020 Date Completed: 20221024 Latest Revision: 20230213
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC9585432
DOI: 10.1001/jamanetworkopen.2022.40037
PMID: 36264571
قاعدة البيانات: MEDLINE
الوصف
تدمد:2574-3805
DOI:10.1001/jamanetworkopen.2022.40037